Loading clinical trials...
Loading clinical trials...
A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy
Conditions
Interventions
Sunitinib (SUTENT)
Locations
1
France
HEGP
Paris, France
Start Date
December 1, 2008
Primary Completion Date
October 1, 2013
Completion Date
October 1, 2013
Last Updated
April 1, 2015
NCT06391099
NCT07227415
NCT06835972
NCT07175480
NCT05700461
NCT05122546
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions